SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is seeing intense community debate following an earnings beat that included raised guidance and strong US commercial growth, with bulls viewing the current stagnant price action as a manipulation-driven buying opportunity while bears emphasize concerns over valuation and the reliance on government contracts.

ARB IOT Group Ltd. is a holding company that engages in the provision of solutions for the integration of IoT systems and devices. It operates through the Internet of Things and Investment Holding and Others segments. The company was founded on March 1, 2022 and is headquartered in Singapore.

ARB IOT Group Ltd

ARBB is trending as traders speculate on a potential short squeeze, driven by its extremely low float and increasing momentum. The community is actively discussing the potential for a parabolic breakout, with many investors holding overnight positions while drawing comparisons to previous low-float market runners.

SKK Holdings Ltd. operates as a holding company, which engages in the provision of civil engineering services in subsurface utility works, including power and telecommunication cable laying, water pipeline and sewer rehabilitation works. The company was founded by Chun Seong Ng and Koon Kiat Sze on October 16, 2013 and is headquartered in Singapore.

SKK Holdings Ltd. - Ordinary Shares - Class A

SKK Holdings Ltd

SKK Holdings is experiencing extreme volatility and rapid price appreciation driven by a major drone asset acquisition agreement, leading to a polarized community debate between traders capitalizing on the micro-float momentum and skeptics warning of potential dilution risks. Investors are actively discussing the stock's thin float, frequent trading halts, and its potential to replicate the parabolic moves of other low-float runners, while critics emphasize concerns over the company's past financial performance and the long-term impact of its acquisition strategy.

Duolingo, Inc. is a language-learning website and mobile application, which engages in the development of a free language learning website and crowd sourced text translation platform. It offers Duolingo for Schools, a free, web-based tool that aims to make it easier for teachers to use the Duolingo platform in a structured learning environment, and English Test, an online, on-demand assessment of English proficiency. The company was founded by Luis von Ahn and Severin Hacker in 2011 and is headquartered in Pittsburgh, PA.

Duolingo Inc - Ordinary Shares - Class A

Duolingo Inc

Duolingo is facing intense market skepticism as investors debate whether generative AI poses a structural threat to its language-learning model or if the current sell-off represents an oversold buying opportunity. While bulls point to strong user engagement metrics and the company's long-term habit-retention moat, bears argue that decelerating growth and aggressive competition from free AI tools signal a permanent shift in the company's outlook.

Pinterest, Inc. engages in the operation of a pinboard-style photo-sharing website. It allows users to create and manage theme-based image collections such as events, interests, and hobbies. The company was founded by Benjamin Silbermann, Paul Cahill Sciarra, and Evan Sharp in October 2008 and is headquartered in San Francisco, CA.

Pinterest Inc - Ordinary Shares - Class A

Pinterest Inc

Pinterest is trending following an aggressive $1 billion investment from Elliott Investment Management and the announcement of a massive $3.5 billion share repurchase program, sparking community debate over the company's long-term valuation. Investors are actively discussing whether this influx of capital and the focus on buybacks will stabilize the stock or if the company remains a potential M&A target.

CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. Its product pipeline includes berubicin, and CNS-12. The company was founded by Waldemar Priebe in July 2017 and is headquartered in Houston, TX.

Cns Pharmaceuticals Inc

Cns Pharmaceuticals is seeing intense volatility and massive volume following an oversubscribed private placement financing, sparking heavy retail interest. The community is actively debating the stock's potential for further squeeze-driven gains versus the risks of dilution, with many focusing on its low float and ongoing technical battles between bulls and short sellers.

Xanadu Quantum Technologies Ltd. engages in the provision of quantum computing solutions for enterprise and government customers. The company was founded by Christian Weedbrook on October 2, 2025 and is headquartered in Toronto, Canada.

Xanadu Quantum Technologies Ltd. - Ordinary Shares - Class B (Sub Voting)

Xanadu Quantum Technologies is experiencing extreme volatility driven by the expiration of post-SPAC lock-up periods, which triggered a massive influx of available shares and intense speculative trading. While some investors fear significant dilution and see a potential for a long-term price reset, others are actively debating whether the sell-off is a panic-induced overreaction that creates a prime opportunity for a short squeeze or a bargain entry point.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle is trending following the CLARITY Act's progress and broader crypto sector gains, though community discussion remains split between strong bullish sentiment regarding its stablecoin infrastructure and concerns over legislative volatility. Investors are closely tracking technical levels and potential institutional adoption as the stock demonstrates sharp price expansion and heavy option volume.

Mask Network is the core product of Dimension, which is positioned to become the bridge that connects internet users from Web 2.0 to Web 3.0. The foundational technology of Mask Network is a peer-to-peer encrypted messaging application, with new functions continuously being created around this foundation. We at Mask Network are strong believers in the ownership economy. People should own what they produce, people should own their data, their attention and the virtual space they choose to contribute to.  Mask Network integrates decentralized social messaging, borderless payment network, and decentralized file storage and sharing to provide a safe and convenient portal for users to jump right into the continent of decentralized finance and then the new world of Web 3.0.

Mask Network

Mask Network is experiencing significant volatility and surging interest, fueled by a new convertible note agreement with institutional investors that provided immediate capital for its AI infrastructure and Nordic data center expansion. The community is actively debating the stock's potential for a momentum-driven breakout against its low-float profile, with traders closely monitoring its connection to the broader AI and compute-shortage narrative.

SEAM is the governance token of Seamless Protocol, the first decentralized, native lending and borrowing protocol on Base.

Seamless

Seamless Protocol ($SEAM) is currently sparking intense debate on social platforms, with a vocal community split between bulls betting on a rebound based on its low circulating supply and bears dismissing the project as a slow-moving rug pull. Investors are closely watching for potential volatility as proponents highlight Coinbase network integration, while critics point to persistent selling pressure from top holders and a lack of transparency regarding the team's identity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Monday Sector Leaders: Biotechnology, Oil & Gas Refining & Marketing Stocks

In trading on Monday, biotechnology shares were relative leaders, up on the day by about 2.1%. Leading the group were shares of Insight Molecular Diagnostics, up about 22.8% and shares of Replimune...

Short Interest in Replimune Group, Inc. (NASDAQ:REPL) Grows By 12.8%

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) was the target of a large increase in short interest in April. As of April 15th, there was short interest totaling 18,426,035 shares, an increase...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...

Replimune Group (NASDAQ:REPL) Cut to "Strong Sell" at Wall Street Zen

Wall Street Zen downgraded shares of Replimune Group from a "sell" rating to a "strong sell" rating in a research note on Saturday...

TRT for Massive Gains

If you’re tired of getting sand kicked in your portfolio’s face, some of these stocks are hitting the gym and flexing. Not every stock here is ripped yet, but several are clearly bulking, a few are cutting into definition, and one or two might already be stepping on stage. $KBLB, $TZOO, $TRT, $AKAN, $TXN, $AUUD, $REPL

<ul class="summary-bullets"><li>FDA refused to approve Replimune’s melanoma drug RP1 for the second time earlier this month, citing insufficient data to provide “substantial evidence of effectiveness.”</li><li>Doctors also called for a change in leadership at the FDA over its decision not to approve Replimune’s RP1.&nbsp;</li><li>According to a report from Reuters, Health Secretary Robert F. Kennedy Jr. told a Senate hearing on Wednesday that he had little role in the FDA’s decision to reject RP1.</li></ul>Shares of Replimune (REPL) jumped 22% on Wednesday after doctors who treat melanoma expressed disappointment over the U.S. Food and Drug Administration’s rejection of the company’s experimental drug RP1.FDA refused to approve Replimune’s melanoma drug RP1 for the second time earlier this month, citing insufficient data to provide “substantial evidence of effectiveness” in the treatment of unresectable advanced cutaneous melanoma.Doctors, in an opinion piece <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/opinion/fda-rp1-replimune-melanoma-drug-rfk-jr-vinay-prasad-marty-makary-b8d666b2?mod&amp;#61;Searchresults&amp;pos&amp;#61;1&amp;page&amp;#61;1">published</a> in The Wall Street Journal, criticized the FDA’s decision, noting that the initial panel that reviewed RP1 had recommended approval, which was later overruled by the then-FDA biologics chief, Vinay Prasad.The second team that reviewed the drug also did not say that the drug was ineffective, instead saying that it is “unclear whether the drug was effective,” the doctors said. Melanoma doctors organized and sent a letter to the FDA imploring it to approve RP1, they noted, while adding that they weren't asked by the pharma industry to do it.“Denying patients a life-saving medicine for inexplicable reasons is the wrong kind of change. If Dr. Makary doesn’t understand that, the FDA needs a change in leadership,” the doctors said.<h2 class="st-heading-2">Kennedy Distances Self</h2>According to a report from <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/legal/litigation/us-health-secretary-kennedy-distances-himself-fdas-replimune-cancer-drug-2026-04-22/">Reuters</a>, Health Secretary Robert F. Kennedy Jr. told a Senate hearing on Wednesday that he had little role in the FDA’s decision to reject R1.He, instead, said that the decision was in the hands of FDA Commissioner Marty Makary."This decision comes out of FDA, and we trust ​the process there,” Kennedy reportedly said.<h2 class="st-heading-2">Replimune’s Efforts With RP1 Approval</h2>In late July 2025, the FDA had issued a complete response letter regarding the company’s application for RP1 in combination with Nivolumab for the treatment of advanced melanoma.The agency said in the letter then that it is unable to approve the application in its present form, and indicated that the trial conducted by the company for the drug is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness. It further urged that the company conduct and provide the results from a fresh trial for further consideration.Replimune subsequently resubmitted its application in October with additional information and analyses, but no additional trial.Earlier this month, the FDA said that the revised application does not alter its initial conclusion of the ineffectiveness of the trials conducted by the company. The agency also noted that the members of the team who reviewed the resubmission were different from those who reviewed the initial application to maintain objectivity.Replimune can either resubmit or withdraw its application within a year.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around REPL stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed within ‘extremely low’ levels.A Stocktwits user opined that “REPL is done for the next two years” and added that the company needs a lifeline from another company.<stembedurl>https://www.stocktwits.com/CanaryMarketIntel/message/651056221</stembedurl>Another user reiterated confidence in the FDA’s decision to reject the drug.<stembedurl>https://www.stocktwits.com/PensionPulse/message/651038201</stembedurl>Another user, however, said that they are looking for 30X gains on REPL stock.<stembedurl>https://www.stocktwits.com/Rookie_investor/message/651040943</stembedurl><a href="https://stocktwits.com/symbol/REPL">REPL stock</a> has fallen 74% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/ual-goes-silent-on-airline-merger-speculation-following-aal-snub/cZBBCayReb7">UAL Goes Silent On Airline Merger Speculation Following AAL Snub</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

REPL Ignites On Doctor Fury Against FDA’s Melanoma Drug Snub — Health Sec Steps Back

Doctors, in an opinion piece published on The Wall Street Journal, criticised the FDA’s decision, noting that the initial panel that reviewed RP1 recommended approval. 

Equity

Doctors, in an opinion piece published on The Wall Street Journal, criticised the FDA’s decision, noting that the initial panel that reviewed RP1 recommended approval. 


Investors Purchase Large Volume of Replimune Group Call Options (NASDAQ:REPL)

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) was the target of unusually large options trading activity on Wednesday. Investors acquired 5,950 call options on the company. This is an...

Replimune Group FY2026 EPS Estimate Lifted by HC Wainwright

Replimune Group, Inc. (NASDAQ:REPL - Free Report) - Equities researchers at HC Wainwright lifted their FY2026 earnings estimates for Replimune Group in a research report issued to clients and...

<ul class="summary-bullets"><li>REPL came under pressure after the FDA issued a second Complete Response Letter for RP1 with nivolumab in anti-PD-1-failed melanoma.</li><li>HOTH declined after a $2 million stock offering, along with attached warrants, raised dilution concerns despite recent pipeline updates.</li><li>ONCO is on a major slide after its reverse stock split, while its pending all-stock acquisition of Realbotix has yet to improve investor sentiment.</li></ul>Shares of Replimune (REPL), Hoth Therapeutics (HOTH), and Onconetix (ONCO) hit fresh 52-week lows on Monday following an FDA setback, a discounted offering, and a reverse split that underscored listing-compliance pressure.&nbsp;On Monday,&nbsp;<a href="https://stocktwits.com/symbol/REPL">REPL</a> fell 64%,&nbsp;<a href="https://stocktwits.com/symbol/HOTH">HOTH</a> slipped 1% and&nbsp;<a href="https://stocktwits.com/symbol/ONCO">ONCO</a> declined 27%, while the Health Care Select Sector SPDR Fund (XLV) rose 0.5%.<h2 class="st-heading-2">Regulatory Setback Pressures REPL Shares Again</h2>Pressure on REPL intensified recently after the U.S. Food and Drug Administration (FDA) issued a second Complete Response Letter (CRL) for its lead drug RP1 in combination with Nivolumab in anti-PD-1-failed melanoma, extending regulatory uncertainty that had already followed an earlier CRL last year.The latest development triggered a wave of&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/repl-stock-on-track-to-hit-all-time-lows-here-s-why-this-analyst-slashed-price-target-by-85/cZJFHklRIMD">analyst downgrades</a> across Wall Street. Jefferies said the company faces “a tough road ahead” following the FDA’s response, while BMO Capital said the CRL “lays bare the lack of alignment with the FDA and Replimune” throughout clinical development and warned the revised regulatory pathway may now require additional trials.JPMorgan called the outcome “disappointing,” adding it had previously believed “the totality of the data for RP1 warranted an approval.”&nbsp;<h2 class="st-heading-2">Stock Offering Weighs On HOTH Stock</h2>HOTH declined after the company announced earlier this month a stock offering priced at $0.7 per share, expected to generate about $2 million in gross proceeds before expenses, along with warrants exercisable at $0.85.The financing overshadowed pipeline updates over the past month, when the company reported interim Phase 2 progress for HT-001, a topical therapy to treat skin toxicities caused by epidermal growth factor receptor (EGFR) inhibitor cancer treatments. The trial showed that patients reached the primary efficacy endpoint by the sixth week and demonstrated “strong patient benefit across multiple clinically meaningful measures.”&nbsp;However, shares caught a break in after-hours trading on Monday, jumping over 60%, after preclinical data showed its&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-hoth-stock-up-after-hours-today/cZJ8gnKRIuz">HT-VA (GDNF) therapy</a> improved key gene markers linked to fat production and metabolism and outperformed Novo Nordisk's semaglutide on liver-fat regulation signals.<h2 class="st-heading-2">ONCO Slides Despite Realbotix Merger Progress</h2>ONCO shares have remained weak since the company implemented a 1-for-5 reverse stock split, effective March 25, to maintain compliance with Nasdaq’s minimum bid price requirement.The reverse split followed a September equity raise of $12.9 million through Series D preferred stock and warrants, with proceeds used in part to reduce outstanding debt and support working capital following the termination of a previously planned merger with Ocuvex.In February, the company entered into an agreement to acquire Realbotix in an all-stock transaction expected to close in the second half of 2026. Realbotix reported delivering its first Vinci-equipped humanoid robot to Ericsson this month and said the platform enables robots to “recognize returning users, recall previous conversations, and track engagement.” The company expects deliveries of 19 robots across March, April and May as production scales.<h2 class="st-heading-2">How Do Retail Traders Feel About REPL, HOTH, ONCO?</h2>On Stocktwits, retail sentiment for REPL was ‘bearish’ amid ‘extremely high’ message volume, while sentiment for both HOTH and ONCO remained ‘extremely bullish,’ also accompanied by ‘extremely high’ message volume.Over the past year, REPL has fallen 77%, HOTH down 36% and ONCO declining 97%, with all three stocks underperforming the broader XLV ETF, which rose 10% over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/immunitybio-founder-fda-warning-letter-anktiva-ad-never-aired/cZJpYnYRIHR">ImmunityBio Founder Pushes Back After FDA Warning Letter Over Anktiva Claims — Says Ad 'Never Aired At All'</a>

On Monday alone, REPL plunged 64%, ONCO dropped 27%, and HOTH slipped 1%. (Photo credit: Getty Images)

REPL, HOTH, ONCO Stocks Hit 52-Week Lows: What's Driving The Selloff In These Biotech Plays?

On Monday alone, REPL plunged 64%, ONCO dropped 27%, and HOTH slipped 1%, underperforming the broader XLV healthcare ETF.

Replimune Gets Second FDA CRL for Melanoma Drug BLA, Stock Crashes

REPL stock plunges after a second FDA CRL delays RP1 melanoma approval, casting doubt on its regulatory path and near-term growth plans.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.65	--	--	N/A
Q3 '25	-$0.76	-$0.77	-0.90%	MISSED
Q2 '25	-$0.74	-$0.90	-21.56%	MISSED
Q1 '25	-$0.79	-$0.95	-19.57%	MISSED
Q4 '24	-$0.72	-$0.82	-14.42%	MISSED

REPL
Replimune Group Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest REPL News

REPLReplimune Group Inc